The blood-brain barrier (BBB) represents a formidable challenge in CNS drug delivery, with approximately 98% of small molecule drugs and nearly all large molecule therapeutics failing to reach the brain in therapeutically relevant concentrations. For Alzheimer's disease (AD), this limitation has significantly constrained the development of disease-modifying therapies targeting pathological proteins, neuroinflammatory pathways, and neurotrophic mechanisms within the central nervous system.
Companies developing intranasal and alternative brain delivery approaches represent an innovative segment of the AD therapeutic landscape. These approaches aim to bypass or transiently modulate the BBB to enable direct CNS delivery of therapeutics, potentially offering advantages in efficacy, safety, and patient convenience compared to traditional systemic delivery with BBB-penetrant small molecules.
Intranasal delivery exploits the unique anatomical connections between the nasal cavity and the brain via olfactory and trigeminal neural pathways, enabling direct nose-to-brain drug transport without systemic exposure. This approach is particularly relevant for peptides, proteins, and cell-based therapies that cannot cross the BBB through conventional means.
Cynata Therapeutics (ASX: CYP) is an Australian biotechnology company developing an induced Mesenchymal Stem Cell (iMSC) platform for neurodegenerative diseases, including Alzheimer's disease. Their CYP-001 product is being explored for intranasal delivery to leverage the immunomodulatory and neuroprotective properties of MSCs.
Otsuka Holdings (TSE: 4578) is a Japanese pharmaceutical company with significant CNS programs in Alzheimer's disease. While primarily known for psychiatric and renal disease therapeutics, Otsuka has invested in alternative delivery technologies for CNS disorders.
Sunovion is a subsidiary of Sumitomo Pharma (formerly Sumitomo Dainippon Pharma) focused on CNS and psychiatric disorders. The company has explored intranasal delivery platforms for CNS therapeutics.
Regeneron Pharmaceuticals (NASDAQ: REGN) is a leading biotechnology company with a significant neuroscience portfolio. While primarily focused on antibody-based therapeutics, Regeneron has invested in brain delivery technologies to expand the reach of their large molecule pipeline to CNS targets.
Astellas Pharma (TSE: 4502) is a Japanese pharmaceutical company with a growing neuroscience portfolio. Astellas has explored intranasal delivery of neurotrophic factors including Nerve Growth Factor (NGF) for neurological disorders.
Beyond intranasal delivery, several companies are developing technologies to enable or enhance brain delivery of therapeutic molecules through BBB modulation, receptor-mediated transcytosis, or other innovative mechanisms.
Denali Therapeutics (NASDAQ: DNLI) is a biotechnology company pioneering the development of therapeutics for neurodegenerative diseases using engineered BBB-crossing platforms. Their Transport Vehicle (TV) technology enables CNS delivery of large molecules.
Biogen (NASDAQ: BIIB) is a leader in Alzheimer's disease therapeutics with approved therapies Leqembi and pipeline programs. The company has invested in brain delivery technologies to enhance CNS penetration of large molecule therapeutics.
Eli Lilly (NYSE: LLY) has developed significant brain delivery capabilities for their neuroscience pipeline, including donanemab and remternetug for Alzheimer's disease. Their antibodies utilize BBB-penetrant engineering.
Roche (SIX: RO) has invested in brain delivery technologies through their partnership with Denali on the Transport Vehicle platform, as well as internal BBB modulation programs.
Companies developing focused ultrasound technology for temporary BBB opening represent an alternative approach to brain delivery:
Several companies are exploring exosome-mediated delivery for CNS therapeutics:
| Company | Technology | AD Program Focus | Stage |
|---|---|---|---|
| Cynata Therapeutics | iMSC intranasal delivery | Immunomodulation | Preclinical/Phase 1 |
| Denali Therapeutics | Transport Vehicle platform | Amyloid, Tau | Phase 1/2 |
| Biogen | BBB-penetrant antibodies | Amyloid (Leqembi), Tau | Approved/Phase 1 |
| Eli Lilly | BBB-penetrant antibodies | Amyloid (Donanemab), Tau | Approved/Phase 1-3 |
| Roche | TV platform, BBB modulation | Amyloid, Tau | Phase 1-3 |
| Regeneron | Brain delivery technologies | Amyloid, Neuroinflammation | Preclinical/Phase 1 |
| Astellas | Intranasal NGF | Neurotrophin delivery | Research |
| Sunovion | Nasal delivery formulations | CNS targets | Discovery |
The brain delivery technology market for AD represents a significant opportunity:
The brain delivery technology landscape is characterized by: